MyFinsight
Home
Compare
Blog
About
Proceeds from initial
public offering, net of...
$320,850K
Proceeds from the
exercise of stock options
$4K
Net cash provided by
financing activities
$316,673K
Canceled cashflow
$4,181K
Increase (decrease) in
cash and cash...
$171,887K
Canceled cashflow
$144,786K
Payment of offering
costs
$4,136K
Payments of issuance
costs associated with...
$45K
Maturities of marketable
securities
$16,390K
Proceeds from sale of
marketable securities
$1K
Stock-based compensation
expense
$2,790K
Prepaid expenses and
other current assets
-$316K
Non-cash operating lease
expense
$112K
Depreciation
$110K
Amortization of debt discount
and deferred...
$17K
Net cash provided by
investing activities
-$118,710K
Net cash used in
operating activities
-$26,076K
Canceled cashflow
$16,391K
Canceled cashflow
$3,345K
Purchases of marketable
securities
$134,832K
Net loss
-$28,935K
Purchases of property and
equipment
$269K
Amortization and accretion of
premiums/discounts on marketable...
$180K
Operating lease liability
-$122K
Accounts payable
-$93K
Accrued liabilities
-$79K
Other assets
$12K
Back
Back
Cash Flow
Avalyn Pharma Inc. (AVLN)
Avalyn Pharma Inc. (AVLN)
source: myfinsight.com